ArticleFrontiers in psychiatry2026
Long-term psychological and functional outcomes after hepatitis C eradication with direct-acting antivirals: an 80-month follow-up study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Direct-acting antivirals (DAAs) have dramatically changed hepatitis C virus (HCV) treatment, by achieving high virological cure rates and a reduced percentage of adverse events compared with previous treatments. Despite this, long-term psychiatric and quality-of-life (QoL) outcomes after viral eradication remain insufficiently understood. This study provides an 80-month follow-up of a previously evaluated cohort. Methods: Of the original 62 patients, 24 (38.7%) were reassessed approximately 80 months after DAA initiation. Psychopathological symptoms (HAM-D, HAM-A, SCL-90-R), coping strategies (COPE), and QoL (SF-36) were evaluated and compared with baseline (T0). Patients were stratified by psychiatric history (Group P vs. Group NP). Non-parametric tests and exploratory correlations and regressions were performed. Results: In Group P, depressive and anxiety symptoms significantly improved from T0 to follow-up (HAM-D: 16 vs. 3, p < 0.01; HAM-A: 15 vs. 4, p < 0.01), with additional reductions in SCL-90-R Interpersonal Sensitivity, Paranoid Ideation, and Psychoticism (all p < 0.05). Group NP showed stable psychological profiles, reflecting the maintenance of improvements already observed at T1, with significant reductions in HAM-D (7 vs. 4, p < 0.01) and HAM-A (8 vs. 4, p < 0.001). Both groups demonstrated a significant decline in SF-36 Physical Component Summary (Group P: p < 0.05; Group NP: p < 0.01). No between-group differences were detected at follow-up. Avoidant coping and psychiatric history were significant negative predictors of long-term anxiety change. Conclusions: Seven years after HCV eradication, psychological well-being remains stable or improved, while physical QoL declines. DAAs demonstrate sustained long-term psychiatric safety, underscoring the need for integrated medical-psychological follow-up in HCV survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.